PDCD1 and renal cell carcinoma: Pembrolizumab, a monoclonal antibody targeting the PD-1 checkpoint, is under investigation both as an adjuvant therapy and as a first-line treatment in RCC, with particularly notable efficacy in clear-cell histology.